The USC School of Pharmacy prides itself on its multi-faceted, collaborative, and translational research enterprise. Our four departments (Clinical Pharmacy, Pharmaceutical Sciences, Pharmaceutical and Health Economics, and Regulatory and Quality Sciences) provide a unique and dynamic landscape for research success; spanning from critical basic science discoveries and key clinical trials, to the translation of those findings into patient care, regulatory and health care policy.
Our relationships within USC, such as the Keck School of Medicine, the Viterbi School of Engineering, and Dornsife College of Letters, Arts, and Sciences, as well as our numerous external academic and industry partnerships, provide invaluable expertise and collaborative potential.
Additionally, we offer a variety of investigative resources to our faculty and collaborators including a translational lab facility, histology lab, lentiviral lab and access to the Optum Clinformatics Data Mart, along with a wide variety of other databases through the Schaeffer Center Data Core. Combined, these resources aim to promote a climate of success for our faculty, students, and collaborators.
USC has the 5th fastest super computer cluster in the US, and Associate Professor Ian Haworth is using it to advance his research in finding new therapies to treat diabetes and neurodegenerative disease.
Searching for Novel Therapies
Several School of Pharmacy faculty are studying signaling pathways in diabetes and liver disease. An exciting new study in collaboration with the City of Hope is examining the potential for islet beta cell – regeneration therapy by inhibiting a key enzyme that plays a role in tumor development and tissue regeneration.
The School unites an interdisciplinary team of pharmacologists, toxicologists and pharmaceutical and regulatory scientists to explore new directions in identifying, designing and targeting new therapeutic advances. Complementing this are researchers working in the clinical arena and in health economics and policy. Centers and institutes, based at the School and throughout the University, offer a structure for collaborative pursuits.
Formulating the Future
Alcohol abuse affects more than 17 million Americans annually. The USC School of Pharmacy is at the forefront of efforts to understand the neurochemical basis of brain function and behavior that is crucial to the development of new approaches to prevent and treat alcoholism, drug abuse and psychological disorders.
A lifetime appointee to the Institute of Medicine, Dr. Goldman leads one of the nation’s premier centers for innovative, independent health policy research. Recent work looks at raising U.S. life expectancy while saving the government $632 billion by 2050.
Dana Goldman, PhD
A two-time NIH Merit Award winner, Dr. Shih won international acclaim for discovering how the brain enzyme monoamine oxidase (MAO) affects behavior. Her research holds promise for treating aggression, depression, alcohol abuse, obesity, autism schizophrenia and cancer.
Jean Shih, PhD
Dr. MacKay’s laboratory is engineering a new generation of bioresponsive nanocarriers designed to more effectively target and destroy cancer cells while sparing healthy tissue and reducing side effects of chemotherapy.
J. Andrew MacKay, PhD
The USC School of Pharmacy is a key partner in the Southern California Clinical and Translational Science Institute (CTSI), funded with a $56.8 million NIH award and aimed at speeding research from the laboratory into sustainable public health solutions.
Solving Public Health Problems
Recipient of one of the first NIH “big idea” awards designed to “encourage projects so original that they have the potential to challenge fundamental beliefs,” Dr. Camarero was recognized for his research to develop a new generation of antibody substitutes.
Julio A. Camarero, PhD
The biotechnology team focuses on drug design, development and delivery, working toward breakthroughs that will transform tomorrow’s medicine by generating new drug compounds for diagnostic and therapeutic use.
Biotechnology Research Team
Increasingly faced with antimicrobial resistance, coupled with the dwindling development of novel agents to treat these infections, faculty combine molecular and pharmacological approaches to address this challenge, while others study defensins, and the mechanisms of infection associated with cystic fibrosis.
Professor Roberta Diaz Brinton has received NIH funding for a clinical trial to evaluate the effectiveness of Allopregnanolone in treating Alzheimer’s disease.
Preventing Alzheimer's Disease
The School of Pharmacy houses research faculty whose work centers on different aspects of cancer – including prostate and brain cancer metastasis, using platform technologies to develop better delivery systems, and identifying small molecule drugs that can interact with key metabolic and signaling pathways.
School of Pharmacy faculty are deeply involved in finding new ways to optimize health outcomes while saving healthcare dollars through projects supported by federal grants.
Prescribing a New Approach
The outcomes research team—including the health economics and policy group, the clinical pharmacy group and the regulatory science group—emphasizes innovations in treatment models and the development of better policies to make sure that care is more accessible and affordable.
Outcomes Research Team
The molecular targets team focuses on the underlying biological mechanisms essential to the development of increasingly targeted and effective treatments for some of the most pervasive and challenging diseases and disorders.
Molecular Targets Research Team
A national expert in improving health outcomes while reducing cost, Dr. Chen is one of the School’s leading faculty serving patients in safety-net clinics, providing medication therapy management for low-income patients with chronic conditions.